NASDAQ · BRNS
Healthcare · Biotechnology
$0.60
Up+$0.06 (+9.43%)
Updated Aug 25, 2026, 11:46 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BRNS closed at $0.60 after 21 trading sessions, up 0.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $0.63 | $0.63 | $0.6031 | $0.6031 | 9.71K |
| Aug 21, 2026 | $0.63 | $0.63 | $0.6191 | $0.6217 | 11.68K |
| Aug 20, 2026 | $0.6262 | $0.6262 | $0.6123 | $0.6123 | 6.49K |
| Aug 19, 2026 | $0.6201 | $0.6508 | $0.5802 | $0.6023 | 9.96K |
| Aug 18, 2026 | $0.616 | $0.66 | $0.615 | $0.62 | 74.58K |
| Aug 17, 2026 | $0.608 | $0.66 | $0.591 | $0.5935 | 44.4K |
| Aug 14, 2026 | $0.58 | $0.63 | $0.5702 | $0.591 | 28.61K |
| Aug 13, 2026 | $0.5849 | $0.5999 | $0.5601 | $0.5999 | 7.11K |
| Aug 12, 2026 | $0.5506 | $0.585 | $0.5506 | $0.5825 | 11.11K |
| Aug 11, 2026 | $0.59 | $0.5999 | $0.5601 | $0.5753 | 8.23K |
| Aug 10, 2026 | $0.59 | $0.60 | $0.5503 | $0.5621 | 21.5K |
| Aug 7, 2026 | $0.58 | $0.599 | $0.55 | $0.599 | 34.88K |
| Aug 6, 2026 | $0.57 | $0.585 | $0.565 | $0.565 | 199.57K |
| Aug 5, 2026 | $0.57 | $0.5801 | $0.57 | $0.5701 | 10.45K |
| Aug 4, 2026 | $0.589 | $0.5999 | $0.5637 | $0.5647 | 83.75K |
| Aug 3, 2026 | $0.60 | $0.6004 | $0.5501 | $0.5999 | 34.36K |
| Jul 31, 2026 | $0.60 | $0.60 | $0.5578 | $0.5578 | 11.36K |
| Jul 30, 2026 | $0.54 | $0.615 | $0.54 | $0.557 | 26.38K |
| Jul 29, 2026 | $0.5875 | $0.615 | $0.556 | $0.5737 | 15.48K |
| Jul 28, 2026 | $0.589 | $0.5925 | $0.5603 | $0.57 | 6.02K |
| Jul 27, 2026 | $0.60 | $0.6075 | $0.60 | $0.601 | 19.74K |
The latest Smart Investors Daily articles mentioning BRNS.
BRNS research
Company profile and research snapshot.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 17, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 13, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 19, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 50 percent increase over losses of $(0.52) per
defenseworld.net · Dec 11, 2025
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Barinthus Biotherapeutics (NASDAQ: BRNS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Valuation and Earnings This table compares Oncobiologics and
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRNS.
